Dr Mayur Raval

Founder & Designated Partner

The pharmaceutical CDMO landscape is evolving rapidly in India and at the global front too. The industry is be ing steered by rapid innovation, regulatory changes, de mand for complex therapies, targeted treatments, faster time to-market, digitalization and sustainability. Given this, CDMOs have come to play an imperative role in enabling collaboration between distinct expertise areas, accelerating patient-centric solutions. Furthermore, clients developing complex formula tions face technical challenges, regulatory uncertainties, scale up risks and limited internal capabilities today.

In this challenging landscape, Verochrom Pharmatech addresses these challenges through specialized expertise, global regulatory support, robust tech transfer, advanced infrastructure, flexible engagement models and a proactive, science-driven approach — ensuring efficient, compliant, and reliable market entry With its innovation-driven mindset, deep expertise in OINDPs, topical dosage forms, and complex injectables, Verochrom Pharmatech combines technical strength with a client-focused approach. This allows for a clear understanding of client requirements and a strong commitment to meeting timelines with precision and consistency.

Fostering a Resilient journey

Verochrom Pharmatech's growth journey has been defined by a steadfast commitment to innovation, quality and client focused collaboration. Over the past five years, the company has steadily expanded its capabilities and consistently delivered successful projects across a wide range of therapeutic areas. Its reputation for regulatory excellence and technical precision has led to long-standing partnerships with global pharmaceutical companies.

The company has successfully executed numerous complex development programs, ranging from early-stage R&D to late phase scale-up and commercialization. This ability to deliver customized, high-quality solutions with speed has positioned the company as a trusted partner in the CDMO space. The commissioning of its state-of-the-art R&D center in Ahmedabad marked a major milestone in its infrastructure enhancement, enabling the team to support high-end development with advanced analytical instruments and automation tools.

In terms of regulatory progress, the company has completed multiple generic formulation projects targeting the US, EU, and ROW markets, several of which are in development, tech transfer or filing stages. Additionally, a couple of NDA products currently in the pre-clinical phase have shown promising results in animal models, with preparations underway for their next stage. The company has also entered into strategic collaborations with global pharmaceutical firms to support long-term development programs. Furthermore, it has also expanded into green chemistry and sustainable process development. These milestones reflect Verochrom’s ongoing journey of growth, resilience and innovation with a continued focus on delivering value to clients and advancing pharmaceutical science.

Carving a Niche for Itself

In a competitive CDMO landscape, Verochrom Pharmatech stands out by combining technical excellence with collaborative innovation, regulatory confidence and end-to end reliability. It specializes in complex dosage forms like inhalation, ophthalmic, topical and injectables, which are executed with speed and precision. It blends boutique agility with full-scale infrastructure, ensuring smooth development to-scale transitions, global regulatory expertise and data driven innovation. Its commitment to long-term, trust-based partnerships makes it a future-ready ally for formulation companies and sponsors.

Furthermore, it is known for its end-to-end expertise in formulation development, analytical support, regulatory documentation and tech transfer, especially for complex dosage forms like OINDPs, ophthalmic, topical and injectables. Its “mind-to-market” services cover pre-formulation, pre clinical support, method development, in-vitro bioequivalence, reverse engineering, characterization, stability, regulatory assistance and commercialization. Key USPs include deep niche formulation expertise, global regulatory strength, agile client collaboration and a strong focus on sustainability and quality.

 Clients-Centric Approach

The company nurtures long-term, trust-based client relationships through transparency, collaboration and scientific integrity. By aligning with client goals early on and maintaining open communication throughout development, the team builds confidence and mutual respect. Emphasizing confidentiality, compliance and ethical standards, the company ensures secure handling of sensitive, high-investment projects. “We see each partnership as a shared journey toward innovation, driven by responsiveness, accountability and a commitment to excellence”, states Dr Mayur Raval, Founder & Designated Partner, Verochrom Pharmatech.

Additionally, the company provides end-to-end regulatory support and post-development assistance to ensure product success across its lifecycle. Here, regulatory services include tailored guidance for global submissions (IND, ANDA, NDA), dossier compilation, audit support and timely response to regulatory queries, all aligned with evolving frameworks. For technology transfer and scale-up, it ensures a smooth transition through structured documentation, on-site training, pilot scale validation, risk mitigation and continuous coordination between development and manufacturing. This ensures efficiency, compliance and minimal disruption.

 Technical Agility 

Verochrom Pharmatech balances speed and compliance through strategic planning, agile execution and strong regulatory insight. With integrated project management, global regulatory expertise and a quality-first approach, the company accelerates development without compromising standards. Additionally, Digital tools and transparent collaboration further ensure fast, effective and fully compliant solutions across multiple markets.

 Further to add with respect to innovation, the company is spearheaded by a multidisciplinary team led by seasoned leaders like Dr Mayur Raval and Dr Nimesh Kalavadia. The team includes project managers, scientists and regulatory experts with extensive experience in complex formulations for global markets. The team’s expertise spans inhalation, topical, ophthalmic and injectable products, with a focus on precision, stability and patient-centric design. The company’s core strength is its team, which helps shape the future of pharmaceutical development.

 A Robust Future Roadmap

Verochrom Pharmatech is preparing for future opportunities through scalable growth, strategic partnerships and continuous capability enhancement. The company is expanding its facilities to handle complex, high-volume projects and collaborating with global pharma companies, academic institutions and technology providers to drive innovation and market readiness.

 Embracing green chemistry and sustainable practices, the company aligns with global environmental goals while reinforcing its scientific and ethical edge. With a growing portfolio and regulatory expertise across geographies, it is poised to enter new markets and therapeutic areas. Dr Mayur concludes by stating, “By a proactive, innovation-led approach, we aim not just to adapt, but to shape the industry's future”.